Saturday, February 23, 2008

Mid Cycle Update

My side effects this chemo cycle have been relatively mild. I seem to be able to more-than-less control them through medication. The clinical trial I began a week ago to alleviate fatigue has worked for me. I say this with some hesitation. As mentioned in the prior blog entry, this is a double blind study. As such, I don’t know whether I’m getting a drug or a placebo. But, whichever it is, it’s working. On the 1 to 10 scale where 1 is no fatigue and 10 is the worst fatigue; I was pretty much at a steady 5 on average prior to last week. I must qualify this by saying my scale is different today than before cancer. In today’s world, a 1 means I feel like I can begin doing a light workout. In the world before cancer, I would have rated myself an 8 or 9 on the fatigue scale. Cancer has a way of changing your perspective on many fronts. The new drug I’m taking has lessened my fatigue level to a 2 or 3. That’s a major improvement both physically and mentally. I found an article on the Internet addressing the use of a drug for cancer-related fatigue. Here’s the URL for those that are interested…

http://www.cancerwise.org/april_2004/display.cfm?id=165dd531-c8c3-422c-bdcbde72034d9f8c&method=displayfull&color=green

I asked the clinical trial administrator if I would ever find out whether it is the drug or the placebo that I’m taking. She wasn’t sure, but will try to find out. I’ll let you know the answer if I get one.

The only other news of note is an upcoming CT scan. It’s scheduled for March 5th. The results will be available around March 10th. Given my history, scan results can at best be neutral news (no clear evidence of disease) and at worst bad news. My last scan was in mid November. Here again, I’ll keep you posted.

I finished two more novels by Lee Child. For those interested in action, suspense, puzzles, and clues, this may be a good read. I know I have enjoyed his works.

I hope all of you are feeling good and healthy. Thanks for checking in. Take care.

No comments: